Jump to content
Sclero Forums
Sign in to follow this  
janey

Vidofludimus Superior to Cyclophosphamide (CYC) and MMF (cellcept) in an Experimental Systemic Lupus Erythematosus (SLE) Model

Recommended Posts

EULAR 2011 - Vidofludimus Superior to Cyclophosphamide (CYC) and MMF (cellcept) in an Experimental Systemic Lupus Erythematosus (SLE) Model.

 

Vidofludimus was as effective as CYC and MMF in inhibiting progression parameters of renal disease. Furthermore, vidofludimus improved activity and chronicity indices, markers of renal inflammation. Business Wire. 05/27/11. (Also see: Lupus)

 

These items were posted in the ISN Newsroom. Check the Newsroom every day for the latest scleroderma medical and support information.


Janey Willis

ISN Support Specialist

(Retired) ISN Assistant Webmaster

(Retired) ISN News Director

(Retired) ISN Technical Writer for Training Manuals

International Scleroderma Network (ISN)

Share this post


Link to post
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
Sign in to follow this  

×